Phenominer Database Results (144 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
DA/Bkl post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 70 days-105 days 10 14.4 d 1.3 4.11 in vivo visual assessment 0.0 0 69554 1158
DA/Bkl calculated serum anti-porcine type 2 collagen antibody titer type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 blood immunoglobulin amount both 66 days-126 days 105 19.0 null 0.59 6.0 enzyme linked immunosorbent assay 0.0 immunized 10 days variable titer 69962 850
BN/SsN calculated serum anti-porcine type 2 collagen antibody titer type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 blood immunoglobulin amount both 66 days-126 days 13 3.0 null 0.55 2.0 enzyme linked immunosorbent assay 0.0 immunized 10 days variable titer 69964 850
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 21 11.7 d 2.23 10.2 in vivo visual assessment 0.0 0 69490 837
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 13 100.0 % in vivo visual assessment 0.0 0 69715 1162
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69723 1162
DA/Ztm serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120 days-180 days 12 790.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69756 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120 days-180 days 14 500.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69758 1162
DA.PVG.1AV1-(D4Rat155-Spr) maximum body weight loss to initial body weight ratio type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass both 120 days-200 days 14 12.5 % 0.9 3.37 body weighing method 0.0 0 69800 1162
DA.PVG.1AV1-(D4Mgh17-D4Rat56) maximum body weight loss to initial body weight ratio type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass male 120 days-200 days 13 6.6 % 1.3 4.69 body weighing method 0.0 0 69803 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 12 100.0 % in vivo visual assessment 0.0 0 69709 1162
PVG.1AV1 percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 33.0 % in vivo visual assessment 0.0 0 69710 1162
DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 8 14.4 d 1.73 4.9 in vivo visual assessment 0.0 0 84923 1301
DA.PVG.1AV1-(D4Got126-D4Got136) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 14 19.0 d 1.18 4.4 in vivo visual assessment 0.0 0 84924 1301
DA.LEW.1AV1-(D4Mgh17-D4Mgh21)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 14 0.0 % in vivo visual assessment 0.0 0 84873 1301
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 100.0 % in vivo visual assessment 0.0 0 84883 1301
DA/ZtmKini thymus weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. thymus mass male 0 days 8 0.6 mg/g 0.07 0.19 post excision weight measurement 0.0 0 84932 1301
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 15.6 d 9.4 in vivo visual assessment 0.0 0 69499 837
DA/ZtmKini inguinal lymph node wet weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. inguinal lymph node mass male 0 days 8 0.68 g/kg 0.07 0.21 post excision weight measurement 0.0 0 84927 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 14 100.0 % in vivo visual assessment 3024000.0 0 70147 1299
DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 55.0 % in vivo visual assessment 0.0 0 84889 1301
DA/ZtmKini liver weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. liver mass male 0 days 8 28.96 g/kg 0.64 1.8 post excision weight measurement 0.0 0 84933 1301
LEW/SsNHsd percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait not specified 77 days-105 days 6 0.0 % in vivo visual assessment 0.0 0 97068 1158
PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 16 20.2 d 2.98 11.9 in vivo visual assessment 0.0 0 84910 1301
DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 17.0 d 0.93 2.8 in vivo visual assessment 0.0 0 84900 1301
F344/NHsd percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 10 30.0 % in vivo visual assessment 3024000.0 0 70149 1299
DA.F344-(D10Arb20-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 10 100.0 % in vivo visual assessment 3024000.0 0 70153 1299
DA.PVG.1AV1-(D4Rat155-Spr) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 13.7 d 0.43 1.5 in vivo visual assessment 0.0 0 70198 1301
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 100.0 % in vivo visual assessment 0.0 0 70199 1301
DA/Bkl post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 70 days-105 days 12 15.8 d 3.3 11.43 in vivo visual assessment 0.0 0 69553 1158
BBDR/Rhw percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait male 66 days-126 days 11 100.0 % in vivo visual assessment 0.0 0 69921 1241
BN/SsN percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 joint integrity trait both 66 days-126 days 13 0.0 % in vivo visual assessment 0.0 immunized 10 days variable 69961 850
DA/Ztm serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120 days-180 days 10 600.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69769 1162
DA/Ztm post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 14.2 d 0.4 1.26 in vivo visual assessment 0.0 0 69790 1162
DA.PVG.1AV1-(D4Mgh17-D4Rat56) maximum body weight loss to initial body weight ratio type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass both 120 days-200 days 11 0.7 % 1.6 5.31 body weighing method 0.0 0 69801 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 71.0 % in vivo visual assessment 0.0 0 69711 1162
DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 10 100.0 % in vivo visual assessment 0.0 0 84879 1301
DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 100.0 % in vivo visual assessment 0.0 0 84875 1301
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 14 64.0 % in vivo visual assessment 0.0 0 84886 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male 0 days 24 100.0 % in vivo visual assessment 0.0 0 84465 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 15 93.0 % in vivo visual assessment 0.0 0 84469 1301
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 13.3 d 0.54 1.8 in vivo visual assessment 0.0 0 84922 1301
DA.PVG.1AV1-(D4Mgh17-D4Rat56) serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount male 120 days-180 days 13 540.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69762 1162
DA/Ztm post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 9 15.2 d 0.2 0.6 in vivo visual assessment 0.0 0 69782 1162
DA.F344-(D10Rat204-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait female 63 days-126 days 10 100.0 % in vivo visual assessment 3024000.0 0 70155 1299
LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 13 15.4 % in vivo visual assessment 0.0 0 70193 1301
DA.PVG.1AV1-(D4Rat155-Spr) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 25.0 % in vivo visual assessment 0.0 0 70197 1301
BBDR/Rhw calculated serum anti-rat type 2 collagen autoantibody titer Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 blood autoantibody amount male 66 days-126 days 11 30.6 null 1.51 5.0 enzyme linked immunosorbent assay 0.0 0 titer 69925 1241
DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 75.0 % in vivo visual assessment 0.0 0 84882 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 15 100.0 % in vivo visual assessment 3024000.0 0 70146 1299
DA.F344-(D10Rat204-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 9 100.0 % in vivo visual assessment 3024000.0 0 70154 1299
DA/Bkl post-insult time to onset of experimental arthritis type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 joint integrity trait both 66 days-126 days 105 15.0 d 0.2 2.0 in vivo visual assessment 0.0 immunized 10 days variable 68143 850
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 5 12.2 d 0.18 0.4 in vivo visual assessment 0.0 0 70196 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 37 5.0 % in vivo visual assessment 0.0 0 70201 1301
ACI/SegHsd percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70 days-145 days 21 5.0 % in vivo visual assessment 0.0 0 69970 1279
BN/SsN percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait female 66 days-126 days 7 0.0 % in vivo visual assessment 0.0 0 69924 1241
BBDR/Rhw calculated serum anti-rat type 2 collagen autoantibody titer Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 blood autoantibody amount female 66 days-126 days 13 31.7 null 1.75 6.3 enzyme linked immunosorbent assay 0.0 0 titer 69926 1241
BN/SsN calculated serum anti-rat type 2 collagen autoantibody titer Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 blood autoantibody amount female 66 days-126 days 7 1.9 null 0.68 1.8 enzyme linked immunosorbent assay 0.0 0 titer 69928 1241
BN/SsN body weight loss type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 body mass both 66 days-126 days 13 0.0 % 0.0 0.0 body weighing method 0.0 immunized 10 days variable (weight loss) 69958 850
DA/Bkl percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 joint integrity trait both 66 days-126 days 105 100.0 % in vivo visual assessment 0.0 immunized 10 days variable 69959 850
DA.PVG.1AV1-(D4Mgh17-D4Rat56) serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120 days-180 days 11 540.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69760 1162
DA.PVG.1AV1-(D4Rat63-D4Rat203) serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120 days-180 days 10 660.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69770 1162
DA/Ztm post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 12 14.5 d 0.5 1.73 in vivo visual assessment 0.0 0 69777 1162
PVG.1AV1 post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 14.6 d 0.4 1.55 in vivo visual assessment 0.0 0 69778 1162
DA.PVG.1AV1-(D4Mgh17-D4Rat56) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 11 15.4 d 0.5 1.66 in vivo visual assessment 0.0 0 69781 1162
DA.PVG.1AV1-(D4Rat155-Spr) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 100.0 % in vivo visual assessment 0.0 0 69712 1162
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 22 15.8 d 1.9 8.9 in vivo visual assessment 0.0 0 69489 837
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 22 19.6 d 2.22 10.4 in vivo visual assessment 0.0 0 69493 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 0 69.0 % 48.0 in vivo visual assessment 0.0 0 visual observation 69498 837
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 12 19.7 d 2.48 8.6 in vivo visual assessment 0.0 0 69376 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 13 69.0 % in vivo visual assessment 0.0 0 68123 837
DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 100.0 % in vivo visual assessment 0.0 0 84877 1301
DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 14.4 d 0.73 2.2 in vivo visual assessment 0.0 0 84915 1301
DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 15.4 d 0.66 2.3 in vivo visual assessment 0.0 0 84921 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male 0 days 24 14.6 d 1.39 6.8 in vivo visual assessment 0.0 0 84467 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 6 100.0 % in vivo visual assessment 0.0 0 84470 1301
DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 17.2 d 1.63 5.4 in vivo visual assessment 0.0 0 84925 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 16.4 d 0.8 2.53 in vivo visual assessment 0.0 0 69791 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) maximum body weight loss to initial body weight ratio type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass both 120 days-200 days 14 2.8 % 1.0 3.74 body weighing method 0.0 0 69799 1162
DA/ZtmKini plasma orosomucoid 1 level Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. orosomucoid 1 amount male 0 days 8 419.0 mg/l 82.02 232.0 radial immunodiffusion assay 0.0 0 84929 1301
DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 10 12.6 d 0.32 1.0 in vivo visual assessment 0.0 0 84918 1301
PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 16 68.8 % in vivo visual assessment 0.0 0 84872 1301
DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 9 22.0 % in vivo visual assessment 0.0 0 84876 1301
DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 100.0 % in vivo visual assessment 0.0 0 84880 1301
LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 13 16.0 d 0.0 0.0 in vivo visual assessment 0.0 0 84903 1301
LEW.1AV1/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 0.0 % in vivo visual assessment 0.0 0 70189 1301
DA/Bkl percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 12 83.3 % in vivo visual assessment 0.0 0 69552 1158
DA/Ztm percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70 days-145 days 36 72.0 % in vivo visual assessment 0.0 0 69969 1279
BN/SsN percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait male 66 days-126 days 13 0.0 % in vivo visual assessment 0.0 0 69923 1241
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 13 22.5 d 3.58 12.9 in vivo visual assessment 0.0 0 69492 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 0 89.0 % 33.0 in vivo visual assessment 0.0 0 visual observation 69497 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 22.5 d 12.9 in vivo visual assessment 0.0 0 69500 837
DA/Ztm serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount male 120 days-180 days 9 590.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69761 1162
DA.PVG.1AV1-(D4Rat155-Spr) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 14.3 d 0.3 1.12 in vivo visual assessment 0.0 0 69780 1162
DA/Ztm maximum body weight loss to initial body weight ratio type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass both 120 days-200 days 12 13.4 % 1.4 4.85 body weighing method 0.0 0 69798 1162
DA/Ztm maximum body weight loss to initial body weight ratio type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass both 120 days-200 days 10 22.8 % 1.1 3.48 body weighing method 0.0 0 69809 1162
DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 43.0 % in vivo visual assessment 0.0 0 84881 1301
DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 12 13.0 d 0.38 1.3 in vivo visual assessment 0.0 0 84919 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female 0 days 24 91.7 % in vivo visual assessment 0.0 0 84466 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 6 16.3 d 0.94 2.3 in vivo visual assessment 0.0 0 84472 1301
DA/Bkl body weight loss type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 body mass both 66 days-126 days 105 19.0 % 0.49 5.0 body weighing method 0.0 immunized 10 days variable (weight loss) 69960 850
BN/SsN calculated serum anti-rat type 2 collagen autoantibody titer type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 blood autoantibody amount both 66 days-126 days 13 2.0 null 0.55 2.0 enzyme linked immunosorbent assay 0.0 immunized 10 days variable titer 69965 850
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 21 21.9 d 2.47 11.3 in vivo visual assessment 0.0 0 69494 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 10.1 d 9.5 in vivo visual assessment 0.0 0 69502 837
DA.PVG.1AV1-(D4Mgh17-D4Rat56) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 13 15.5 d 0.2 0.72 in vivo visual assessment 0.0 0 69783 1162
DA/Ztm maximum body weight loss to initial body weight ratio type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass male 120 days-200 days 9 7.5 % 2.1 6.3 body weighing method 0.0 0 69802 1162
DA.F344-(D10Arb20-D10Arb22)/Arb percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 10 100.0 % in vivo visual assessment 3024000.0 0 70152 1299
DA.PVG.1AV1-(D4Mgh17-D4Rat56) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 12.4 d 0.49 1.3 in vivo visual assessment 0.0 0 70200 1301
BBDR/Rhw percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait female 66 days-126 days 13 100.0 % in vivo visual assessment 0.0 0 69922 1241
BN/SsN calculated serum anti-rat type 2 collagen autoantibody titer Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 blood autoantibody amount male 66 days-126 days 13 1.3 null 0.28 1.0 enzyme linked immunosorbent assay 0.0 0 titer 69927 1241
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 27 96.3 % in vivo visual assessment 0.0 0 70188 1301
DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 18 89.0 % in vivo visual assessment 0.0 0 84892 1301
F344/NHsd percentage of study population developing experimental arthritis during a period of time type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44. joint integrity trait male 63 days-126 days 10 20.0 % in vivo visual assessment 3024000.0 0 70148 1299
DA/Bkl percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (0.1 ml) Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11 joint integrity trait male 77 days-105 days 10 50.0 % in vivo visual assessment 0.0 0 69551 1158
DA.PVG-(D4Rat141-D4Mgh11) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 30 10.0 % in vivo visual assessment 0.0 0 70191 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 5 100.0 % in vivo visual assessment 0.0 0 70192 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 27 14.0 d 1.06 5.5 in vivo visual assessment 0.0 0 70194 1301
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91 days-112 days 22 82.0 % in vivo visual assessment 0.0 0 visual observation 69487 837
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 20.0 d 8.5 in vivo visual assessment 0.0 0 69501 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 13 10.1 d 2.63 9.5 in vivo visual assessment 0.0 0 69377 837
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69722 1162
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 11 100.0 % in vivo visual assessment 0.0 0 69713 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 9 100.0 % in vivo visual assessment 0.0 0 69714 1162
DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 18 14.8 d 0.75 3.2 in vivo visual assessment 0.0 0 84926 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 14.0 d 0.42 1.4 in vivo visual assessment 0.0 0 84917 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female 0 days 24 14.6 d 0.63 3.1 in vivo visual assessment 0.0 0 84468 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 15 14.9 d 1.52 5.9 in vivo visual assessment 0.0 0 84471 1301
DA/Bkl calculated serum anti-rat type 2 collagen autoantibody titer type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 blood autoantibody amount both 66 days-126 days 105 15.0 null 0.59 6.0 enzyme linked immunosorbent assay 0.0 immunized 10 days variable titer 69963 850
DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 45.0 % in vivo visual assessment 0.0 0 84878 1301
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91 days-112 days 21 76.0 % in vivo visual assessment 0.0 0 visual observation 69488 837
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 12 14.8 d 2.4 8.3 in vivo visual assessment 0.0 0 69491 837
PVG.1AV1 serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120 days-180 days 15 250.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69757 1162
DA.PVG.1AV1-(D4Rat155-Spr) serum orosomucoid 1 level type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120 days-180 days 14 660.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69759 1162
DA.PVG.1AV1-(D4Rat155-D4Rat84) post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 14 17.6 d 0.8 2.99 in vivo visual assessment 0.0 0 69779 1162
DA.PVG.1AV1-(D4Rat63-D4Rat203) maximum body weight loss to initial body weight ratio type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass both 120 days-200 days 10 14.6 % 1.8 5.69 body weighing method 0.0 0 69810 1162
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 12 92.0 % in vivo visual assessment 0.0 0 68122 837
DA.PVG.1AV1-(D4Rat63-D4Rat203) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 37 14.0 d 0.0 0.0 in vivo visual assessment 0.0 0 70202 1301
PVG.1AV1/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 29 0.0 % in vivo visual assessment 0.0 0 70190 1301
DA.PVG-(D4Rat141-D4Mgh11) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 30 31.7 d 1.86 10.2 in vivo visual assessment 0.0 0 70195 1301
DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 8 100.0 % in vivo visual assessment 0.0 0 84884 1301
DA/ZtmKini spleen weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. spleen mass male 0 days 8 0.18 % 0.0 0.01 post excision weight measurement 0.0 0 84931 1301
DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 11 14.9 d 1.03 3.4 in vivo visual assessment 0.0 0 84916 1301
DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 12.7 d 0.45 1.2 in vivo visual assessment 0.0 0 84920 1301
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 7 0.0 % in vivo visual assessment 0.0 0 84874 1301